TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04687995

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic myringoplasty
Description: Endoscopic myringoplasty by using two different grafts one each time

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic myringoplasty
Description: Endoscopic myringoplasty by using two different grafts one each time
Study: NCT05363579

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy
Description: Physiotherapy can be defined as a treatment method that focuses on the science of movement and helps people to restore, maintain and maximize their physical strength, function, motion and overall well-being by addressing the underlying physical issues.

Intervention type: OTHER
Group type: OTHER
Intervention: Tuina therapy
Description: Tuina is mainly applied to the meridians or acupoints by manipulation techniques such as pushing, grasping, pressing and rubbing of the soft tissues or muscles of the body. It is reported to improve circulation and the qi in the body.

Intervention type: OTHER
Group type: OTHER
Intervention: Physio and Tuina therapy
Description: Physiotherapy mixed with Tuina
Study: NCT04346563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape, functional correction technique
Description: According to Kinesio Taping, functional correction technique could use for correcting shoulder, scapular alignment and decrease pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic band strengthening shoulder exercise
Description: The exercise in which both groups will receive Introduction of exercise with rubber bands (Elastic band) It is a home exercise (Home base exercise program) for patients to do with appropriate resistance. Which can be done at least 10 times and not more than 20 times continuously,will be asked to do all 3 positions.~1) Shoulder external rotation in shoulder abduction 90 degrees 2) Shoulder horizontal abduction in shoulder abduction 90 degrees 3) Seated bend row, which will be done 15 times, each hold for 10 seconds, do 3 sets, each set rest 2 minutes, 2 times a day ( Morning-evening) consecutively for 1 week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elastic band strengthening shoulder exercise
Description: The exercise in which both groups will receive Introduction of exercise with rubber bands (Elastic band) It is a home exercise (Home base exercise program) for patients to do with appropriate resistance. Which can be done at least 10 times and not more than 20 times continuously,will be asked to do all 3 positions.~1) Shoulder external rotation in shoulder abduction 90 degrees 2) Shoulder horizontal abduction in shoulder abduction 90 degrees 3) Seated bend row, which will be done 15 times, each hold for 10 seconds, do 3 sets, each set rest 2 minutes, 2 times a day ( Morning-evening) consecutively for 1 week
Study: NCT05462496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Ciprofloxacin and metronidazole will be initiated 7 days following 5th dose of FOLFIRINOX. Subjects will self-administer metronidazole 500mg PO every 8 hours on days 1-21. Participants will be instructed to take the antibiotics with food to minimize stomach upset and to administer at the same time each day. Treatment with antibiotics will continue for 21 days unless there is unacceptable toxicity or disease progression. Subjects will record date, time and number of tablets they take on provided drug diaries.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be initiated 7 days post initiation of antibiotics. Subjects will receive a flat dose of pembrolizumab 200mg IV over 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Following completion of 21 days of antibiotics, participant will undergo repeat imaging studies. If there is no progressive disease which renders participant surgically unresectable (based on NCCN guidelines 2.2021), subject will undergo definitive surgical resection.
Study: NCT06397612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Dose
Description: Patients will be intervened with stimulation continuously, at a frequency of 20 Hertz, a pulse width of 200 µs and for a total of 20 minutes. The intensity will be set at the maximum tolerated by the patient.
Study: NCT05513573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX07
Description: 1500 mg, D1，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: 300 mg, D1, up to 2 years,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: 300 mg, D1, up to 2 years,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 1500 mg, D1，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: gemcitabine 1000 mg/m2, D1,D8; cisplatin 80 mg/m2,D1；Q3W, up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: gemcitabine 1000 mg/m2, D1,D8; cisplatin 80 mg/m2,D1；Q3W, up to 6 cycles
Study: NCT04804345

Intervention type: OTHER
Intervention: standard of care
Description: retrospective study: standard of care

Intervention type: OTHER
Intervention: standard of care
Description: retrospective study: standard of care
Study: NCT05668624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clean household energy
Description: LPG stoves/fuel for cooking and solar electricity for lighting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clean household energy
Description: LPG stoves/fuel for cooking and solar electricity for lighting
Study: NCT05402072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous matrix-induced chondrogenesis (AMIC)
Description: AMIC is a novel approach in which the microfracture technique has been enhanced by the use of a type I/III collagen matrix (Chondro-Gide®; Geistlich Pharma AG, Wolhusen, Switzerland). In this single-step procedure, the matrix is placed over the defect to stabilize the fragile blood clot that arises from microfracture and to provide infrastructure for repair tissue formation. Essentially, the matrix covers the defect and serves as a protective shield that contains the cells and minimizes the impact of shear forces when moving the hip on the delicate blood clot. At the same time, it functions as the roof of a biological chamber that forms over the defect. The biocompatible collagen material provides an environment for cell growth and is replaced by native tissue over time.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous matrix-induced chondrogenesis (AMIC)
Description: AMIC is a novel approach in which the microfracture technique has been enhanced by the use of a type I/III collagen matrix (Chondro-Gide®; Geistlich Pharma AG, Wolhusen, Switzerland). In this single-step procedure, the matrix is placed over the defect to stabilize the fragile blood clot that arises from microfracture and to provide infrastructure for repair tissue formation. Essentially, the matrix covers the defect and serves as a protective shield that contains the cells and minimizes the impact of shear forces when moving the hip on the delicate blood clot. At the same time, it functions as the roof of a biological chamber that forms over the defect. The biocompatible collagen material provides an environment for cell growth and is replaced by native tissue over time.
Study: NCT05708508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROVALCYTE
Description: Immuno-guided strategy arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROVALCYTE
Description: Immuno-guided strategy arm
Study: NCT05802134

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable supplement
Description: Weekly food kits including culturally-appropriate fruits and vegetables (to achieve 8-10 servings per day) and staple items to support DASH diet compliance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and chronic disease management education
Description: Intensive education for chronic disease management: participants will receive education on hypertension management, which will include an interprofessional health appointment with a medical professional to discuss medication compliance, and resources from an occupational therapist for chronic disease management strategies, and 2 nutrition appointments with a Registered Dietitian regarding the DASH Diet (initial education and follow-up at 2 weeks)
Study: NCT05179577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen
Description: Arbaclofen Extended Release Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT05708690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100 MG/ML
Description: Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal saline is a cornerstone of intravenous solutions commonly used in the clinical setting. It is a crystalloid fluid administered via an intravenous solution. Its indications include both adult and pediatric populations as sources of hydration and electrolyte disturbances
Study: NCT05435209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Description: Gardasil
Study: NCT06033612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV299
Description: Oral Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV299
Description: Oral Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV299
Description: Oral Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: pre-filled oral syringe
Study: NCT05214365

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation and conventional cardiac pacing
Description: Patients will have the pacemaker implanted in the electrophysiology laboratory. Electrode will be implanted (in the apical or septal portion) according to the criteria of the implanting physician.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conduction system pacing implant
Description: Right ventricular lead was placed to get his bundle or left bundle branch.
Study: NCT06527027

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lymph node assessment according to RECIST 1.1 in CT
Description: RECIST 1.1 classifies lymph nodes as healthy when they have a short axis dimension (SAD) of \<10 mm; Nodes with a SAD dimension \>=10 mm are considered to be involved in the cancer process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymph node assessment according to Node-RADS in CT
Description: Node-RADS classifies lymph nodes taking into account parameters such as: size, degree of homogeneity, boundaries and shape of the node. Depending on the degree of change in a given parameter, an appropriate number of points are awarded in each category, and the sum of the points determines the final classification of the node into one of five categories of probability of being affected by a cancer process: 1-very low, 2-low, 3-medium, 4 -high, 5-very high.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymph node assessment according to LN-RADS in CT
Description: LN-RADS (Lymph Node Reporting and Data System) categorizes nodes according to a scale that reflects the radiological and clinical forms of the nodes and the level of probability of a malignant process:~LN-RADS 1 - normal lymph node LN-RADS 2 - enlarged and fatty lymph node, not suspected from an oncological point of view LN-RADS 3 - lymph node with features suggesting reactive changes. LN-RADS 4a - lymph node with slight oncological suspicion LN-RADS 4b - lymph node with strong oncological suspicion LN-RADS 5 - definitely cancerous node

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lymph node assessment according to RECIST 1.1 in MRI
Description: RECIST 1.1 classifies lymph nodes as healthy when they have a short axis dimension (SAD) of \<10 mm; Nodes with a SAD dimension \>=10 mm are considered to be involved in the cancer process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymph node assessment according to Node-RADS in MRI
Description: Node-RADS classifies lymph nodes taking into account parameters such as: size, degree of homogeneity, boundaries and shape of the node. Depending on the degree of change in a given parameter, an appropriate number of points are awarded in each category, and the sum of the points determines the final classification of the node into one of five categories of probability of being affected by a cancer process: 1-very low, 2-low, 3-medium, 4 -high, 5-very high.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymph node assessment according to LN-RADS in MRI
Description: LN-RADS (Lymph Node Reporting and Data System) categorizes nodes according to a scale that reflects the radiological and clinical forms of the nodes and the level of probability of a malignant process:~LN-RADS 1 - normal lymph node LN-RADS 2 - enlarged and fatty lymph node, not suspected from an oncological point of view LN-RADS 3 - lymph node with features suggesting reactive changes. LN-RADS 4a - lymph node with slight oncological suspicion LN-RADS 4b - lymph node with strong oncological suspicion LN-RADS 5 - definitely cancerous node
Study: NCT05641896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FAPI-74 PET/CT
Description: \[18F\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastrointestinal cancers.
Study: NCT04647162

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematoma evacuation by craniotomy
Description: The intervention method of hematoma evacuation is under craniotomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematoma evacuation by stereotactic puncture
Description: The intervention method of hematoma evacuation is under stereotactic puncture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematoma evacuation by neuroendoscopy
Description: The intervention method of hematoma evacuation is under neuroendoscopy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: life support
Description: The treatments in medical group includes life support, nutrition support, and rehabilitation therapy。
Study: NCT06530667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: broadband collaborative pulse ablation
Description: Via CT guided, patients with malignant pulmonary nodules would be treated by broadband collaborative pulse ablation
Study: NCT05730205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexplanon 68 MG Drug Implant
Description: Progestin contraceptive device
Study: NCT04759131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efanesoctocog alfa (BIVV001)
Description: Pharmaceutical form: solution for injection Route of administration: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efanesoctocog alfa (BIVV001)
Description: Pharmaceutical form: solution for injection Route of administration: IV
Study: NCT05186545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib + fulvestrant + chidamide
Description: surufatinib: 250 mg/d, QD PO; Fulvestrant: 500mg, im, Q4W; Chidamide 30mg, PO, BIW; Q4W
Study: NCT05521867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic balloon dilation
Description: EBD procedures will be performed with wire guided CRE pneumatic balloon (controlled radial expansion balloon, Boston scientific, Marlborough, MA, USA 0of various sizes based on tightness of the stricture (10-12 mm, 12-15 mm, 15-18 mm, 18-20 mm) with graded dilations with inflation pressures varying from 3-8 ATM pressure. Balloon was inflated for at least 2 minutes and slowly deflated. A maximum of two sessions of dilation will be allowed with a minimum interval of 15-30 days between them.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic stricturotomy with or without stricturoplasty
Description: Endoscopic stricturotomy would be done using either a triple-lumen needle-knife (Boston Scientific, Marlborough, MA) or with a electrosurgical IT knife2 (Olympus Medical Systems, Tokyo, Japan) in the setting of endoscopic retrograde cholangiopancreatography (ERCP) Endocut on Erbe medical device (USA Incorporated Surgical Systems, Marietta, GA) with the following electrocautery settings : Endocut Q (effect 3, cut duration 1, cut interval 3). Strictures will be incised in a circumferential or radial fashion until an adequate passage of the scope. Endoclips may be applied post stricturotomy to act as keep treated stricture open and to prevent delayed bleeding (referred as stricturoplasty). Choice of endoclips and decision to perform stricturoplasty would be at the discretion of endoscopist.
Study: NCT05839600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1821736
Description: Solution for infusion
Study: NCT06099990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
Description: dalpiciclib+ abiraterone+ prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo; abiraterone acetate tablets; prednisone tablets
Description: placebo+abirarerone+prenisone
Study: NCT05039918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective touch
Description: Gentle stroking at CT-optimal speed
Study: NCT05660395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) Infusion
Study: NCT05701462

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biopsy under sonographic gidance
Description: pleural biopsy under sonographic guidance
Study: NCT06016686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VNS stimulation and intraneural recordings
Description: A minimum of three stimulation frequencies (1, 10 and 30 Hz), each up to 60s in duration, will be delivered via the VNS device. Intraneural recordings proximal or distal to the VNS electrodes during delivery of VNS will be performed. Approximately two to five fascicles will be explored in each nerve.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Record multi-unit activity from intraneural sites
Description: Perform a more detailed vagal nerve mapping study by recording from single nerve fibers, including those fibers supplying the heart, lungs, airways and other end-organs. The investigators shall perform functional mapping of the left and right vagus nerves, such as those with cardiac-related and/or respiratory-related neural activity. The research team will also record activity from other nearby fibers to map the differences in neurological behavior in fascicles that control the heart, lungs, airways and other systems.
Study: NCT04286191

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Operant Conditioning
Description: This is a training intervention in which the brain-spinal cord-muscle pathways are strengthened in individuals with incomplete spinal cord injury. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the tibialis anterior (TA), the muscle that lifts your toes and foot.

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: This is the control intervention, or the non-conditioning group. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the tibialis anterior (TA), the muscle that lifts your toes and foot.
Study: NCT05088720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol 800 µg
Description: received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol 400 µg
Description: received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually
Study: NCT06126926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group therapy
Description: 32 weeks of group therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Control participants remain in their current placement and may be eligible for a number of services offered to inmates to facilitate rehabilitation and planning for release to the community, including sexual offender treatment. MnDOC's sexual offender treatment is a two to three year program, thus most of our control subjects will not have enough time remaining on their sentences to complete such treatment. However, a number of them may participate in MnDOC's current program.
Study: NCT06041490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multi-kinase inhibitors in combination with bevacizumab
Description: The eligible participants will start taking multi-kinase inhibitors between 4-8 weeks after liver transplantation. The choice of the specific multi-kinase inhibitor, including sorafenib, lenvatinib, or regorafenib, will be determined by the researchers based on factors such as the participant's tumor characteristics, liver function, physical condition, risk of side effects, economic status, and personal preference. The specific dosage and administration details can be found in the table provided. The maximum duration of multi-kinase inhibitor treatment will be 12 months or until any of the following conditions occur, whichever comes first: 1) The participant experiences intolerable toxic reactions that do not alleviate with dose adjustments, or 2) The participant has documented disease recurrence confirmed through imaging or withdraws from the study for other reasons.
Study: NCT06185751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WS-CART-CS1
Description: -Subject will be hospitalized for 7 days